Compare Tenet Healthcare Corporation (THC) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tenet Healthcare Corporation vs Xylem, Inc. — how do they compare? Tenet Healthcare Corporation trades at $259.45 (market cap $20.93B), while Xylem, Inc. trades at $123.19 (market cap $28.30B). The key difference: Xylem, Inc. is the larger of the two by market cap, and Xylem, Inc. pays a 1.42% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| THC | XYL | |
|---|---|---|
Market Cap | $20.93B | $28.30B |
Sector | Health | Industrials |
52-Week High | $262.63 | $152.95 |
52-Week Low | $161.37 | $106.34 |
Enterprise Value | $32.01B | $30.08B |
Dividend Yield | — | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tenet Healthcare (THC) trades at $262.13, up 2.14% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS beating estimates at $6.12 versus $4.26 expected, while valuation metrics remain attractive with P/E of 10.05 and EV/EBITDA of 5.74. Recent institutional buying and positive earnings revisions support the upward trend.
Outlook remains positive with consensus price target of $281.44 offering 7.4% upside potential. Key risks include healthcare policy headwinds and competitive pressures, but strong ambulatory growth and expense management provide fundamental support. The stock presents a compelling value-growth combination for investors seeking healthcare exposure.
Xylem (XYL) trades at $120.32, down 0.36% on the day, with a neutral technical signal and key support at $120. The company reported strong Q2 2026 earnings of $1.46 per share, beating estimates, and raised its full-year profit guidance. Revenue growth has been steady, reaching $9.04B in 2025, with net income margins improving to 10.59%. Analyst sentiment is mixed, with a consensus price target of $150.43, implying significant upside from current levels.
The outlook for XYL is positive, driven by robust demand in water technology and AI infrastructure, alongside margin expansion. Key risks include project delays in electric metering and competitive pressures. With a P/E of 28.65, the stock trades at a premium, but continued execution on earnings and strategic acquisitions supports a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
